Cardiovascular Prevention for Persons With HIV

Overview

This study is funded by the American Heart Association. The goal of this research is to prevent early cardiovascular damage before symptoms develop for persons with HIV infection. Evidence suggests that taking low doses of blood pressure and cholesterol medication reduces risk for heart disease in persons who are at increased risk (such as the case with HIV infection). Participants who are taking HIV treatment with an 'undetectable' viral load, and who do NOT need treatment for high blood pressure or cholesterol may be eligible to enroll. Participants will take a low dose cholesterol medication (or placebo) and a low dose of a blood pressure medication (or a placebo), and will be seen at 3 study visits over 4 months.

Full Title of Study: “Cardiovascular Disease Risk Reduction for Persons With HIV Infection: a Polypill Pilot Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Factorial Assignment
    • Primary Purpose: Prevention
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: December 2010

Interventions

  • Drug: Pravastatin
    • Participants randomized to take pravastatin (active) or matching placebo pill once daily
  • Drug: Lisinopril
    • Participants randomized to take lisinopril (active) or matching placebo pill once daily

Arms, Groups and Cohorts

  • Experimental: Lisinopril
    • Lisinopril 10mg once daily
  • Placebo Comparator: Lisinopril Placebo
    • Placebo pill (matched to lisinopril) once daily
  • Experimental: Pravastatin
    • Pravastatin 20mg once daily
  • Placebo Comparator: Pravastatin placebo
    • Placebo pill (matched to pravastatin) once daily

Clinical Trial Outcome Measures

Primary Measures

  • Number of Participants Who Stated (by Self-report) That They Had Side Effects
    • Time Frame: 4 months
    • Participants were asked at each visit if they had any side effects to study medication. They provided a yes or no answer, and if yes they specified what the side effect was.
  • Number of Participants Who Took >90% of Their Doses (by Pill Count)
    • Time Frame: 4 months
    • The number of pills missing from study medication bottles was counted by study nurses at the completion of the study. The proportion of pills taken divided by the number of days the participant was enrolled in the study was calculated, and multiplied by 100, to generate the ‘% of doses taken’
  • Change From Baseline to Month 4 in the Framingham Risk Score (FRS)
    • Time Frame: Change from baseline to 4 months
    • The Framingham Risk Score is calculated by a published algorithm that predicts a patients risk of having a coronary heart disease event in the next 10 years. The measures that are considering in predicting this risk are: age, blood pressure, cholesterol (both total cholesterol and high-density lipoprotein cholesterol), smoking status, and use of medication to treat hypertension. This risk score can be estimated using an online calculator (http://hp2010.nhlbihin.net/atpiii/calculator.asp)

Secondary Measures

  • Changes in Blood Pressure
    • Time Frame: change from baseline to 4 months
    • Blood pressure was assessed by standard clinical methods (i.e., the same way it is measured during a routine clinic visit)
  • Changes in Blood Lipids
    • Time Frame: change from baseline to 4 months
    • Blood lipids include routine cholesterol measurements that are monitored in clinical practice. They are measured in blood after a blood draw is performed. The specific measurements include: a) total cholesterol, b) low-density lipoprotein cholesterol, c) high-density lipoprotein cholesterol, and d) triglycerides
  • Changes in Small Artery Elasticity
    • Time Frame: change from baseline to 4 months
    • Small artery elasticity is a measure of vascular function, estimated through analysis of the blood pressure waveform. A sensor is placed on wrist over the radial pulse. The blood pressure waveform of the pulse is recorded and analyzed the elasticity, or compliance, of the small (and large) vasculature. Impaired artery elasticity, or increased stiffness, is an early sign of vascular disease that predicts risk for future cardiovascular events.
  • Changes hsCRP (C-reactive Protein)
    • Time Frame: change from baseline to 4 months
    • This biomarker represents systemic inflammation within in the body.
  • Changes IL-6 (Interleukin-6)
    • Time Frame: change from baseline to 4 months
    • This biomarker represents systemic inflammation within in the body.
  • Changes TNFa (Tumor Necrosis Factor Alpha)
    • Time Frame: change from baseline to 4 months
    • This biomarker represents systemic inflammation within in the body.

Participating in This Clinical Trial

Inclusion Criteria

  • HIV Infection with viral load 'undetectable' while taking antiretroviral therapy – Age ≥40 – Framingham risk score (FRS) ≥5%, or ≥3% with ≥5 years of exposure to antiretroviral therapy Exclusion Criteria:

  • Known cardiovascular disease or Framingham risk score (FRS) ≥20% – Blood pressure ≥140/90 – LDL cholesterol ≥160 (with FRS <10%), or ≥130 (with FRS 10-20%) – Currently taking, or has a medication contraindication to take, a 'statin', an ACE inhibitor, or an angiotensin receptor blocker medication – Cirrhosis or plasma ALT/AST levels >2x upper limit of normal – Chronic kidney disease and a creatinine >2.0mg/dL – Triglycerides >500mg/dL

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hennepin Healthcare Research Institute
  • Collaborator
    • American Heart Association
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jason Baker, MD, Principal Investigator, Hennepin Faculty Associates

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.